Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
Sign Up to like & getrecommendations! Published in 2019 at "Diabetologia"
DOI: 10.1007/s00125-019-4839-8
Abstract: Aims/hypothesisThe primary analysis of the Canagliflozin cardioVascular Assessment Study (CANVAS) Program showed canagliflozin to have a beneficial effect on cardiovascular and renal outcomes in people with type 2 diabetes at high cardiovascular risk, but also… read more here.
Keywords: canvas program; amputation; risk; canagliflozin ... See more keywords
Adverse Drug Events Associated with sitagliptin Versus canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes Therapy"
DOI: 10.1007/s13300-018-0481-6
Abstract: IntroductionIn this meta-analysis, we aimed to systematically compare the adverse drug events associated with sitagliptin (100 mg) versus canagliflozin 100 or 300 mg in patients who were treated for type 2 diabetes mellitus (T2DM).MethodsOnline databases were searched… read more here.
Keywords: canagliflozin; versus canagliflozin; drug; drug events ... See more keywords
Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes Therapy"
DOI: 10.1007/s13300-019-00689-w
Abstract: To investigate canagliflozin-induced changes in postprandial total glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels in patients with type 2 diabetes mellitus (T2DM). Forty-five patients with T2DM who had inadequate glycemic control (glycated… read more here.
Keywords: postprandial total; glp; gip; glucosidase inhibitor ... See more keywords
Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes Therapy"
DOI: 10.1007/s13300-020-00826-w
Abstract: Type 2 diabetes mellitus (T2DM) affects millions of people worldwide, elevating their risk of developing a range of complications, including chronic kidney disease (CKD). People with T2DM and CKD (i.e., diabetic kidney disease, DKD) have… read more here.
Keywords: people t2dm; treatment; disease; canagliflozin ... See more keywords
Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study.
Sign Up to like & getrecommendations! Published in 2017 at "Chemico-biological interactions"
DOI: 10.1016/j.cbi.2017.09.008
Abstract: During preclinical development of canagliflozin, an SGLT2 inhibitor, treatment-related pheochromocytomas, renal tubular tumors (RTT), and testicular Leydig cell tumors were reported in the 2-year rat toxicology study. In a previous 6-month rat mechanistic study, feeding… read more here.
Keywords: rat study; malabsorption; adrenal medullary; canagliflozin ... See more keywords
Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
Sign Up to like & getrecommendations! Published in 2018 at "JACC: Basic to Translational Science"
DOI: 10.1016/j.jacbts.2018.01.010
Abstract: Canagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), was shown to reduce major adverse cardiovascular events in the recent CANVAS (CANagliflozin cardioVascular Assessment Study) program [(1)][1]. Canagliflozin treatment was, however, also associated with a significant increase… read more here.
Keywords: blood flow; canagliflozin improves; improves recovery; canagliflozin ... See more keywords
Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1
Sign Up to like & getrecommendations! Published in 2020 at "Redox Biology"
DOI: 10.1016/j.redox.2020.101527
Abstract: Recent cardiovascular outcome trials found that sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular disease and mortality in type 2 diabetic patients; however, the underlying mechanisms are not fully known. Since the proliferation and migration of vascular… read more here.
Keywords: proliferation migration; canagliflozin; cell; vascular smooth ... See more keywords
Analytical Quality by Design-Assisted HPLC Method for Quantification of Canagliflozin and Stability Studies
Sign Up to like & getrecommendations! Published in 2023 at "ACS Omega"
DOI: 10.1021/acsomega.2c06038
Abstract: The present study is intended to develop the high-performance liquid chromatography (HPLC) method for the analysis of Canagliflozin using the analytical quality by design (AQbD) approach. The key parameters were methodically optimized with the help… read more here.
Keywords: analytical quality; design; canagliflozin; hplc method ... See more keywords
Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice.
Sign Up to like & getrecommendations! Published in 2022 at "Acta pharmacologica Sinica"
DOI: 10.1038/s41401-022-00878-7
Abstract: Canagliflozin is an antidiabetic medicine that inhibits sodium-glucose cotransporter 2 (SGLT2) in proximal tubules. Recently, it was reported to have several noncanonical effects other than SGLT2 inhibiting. However, the effects of canagliflozin on skeletal muscle… read more here.
Keywords: muscle; mice; canagliflozin; muscle regeneration ... See more keywords
Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells
Sign Up to like & getrecommendations! Published in 2022 at "Cell Death Discovery"
DOI: 10.1038/s41420-021-00801-9
Abstract: Sodium-glucose cotransporter 2 inhibitors, which are recently introduced as glucose-lowering agents, improve cardiovascular and renal outcomes in patients with diabetes mellitus. These drugs also have beneficial effects in various kidney disease models. However, the effect… read more here.
Keywords: canagliflozin protects; canagliflozin; protects cisplatin; renal proximal ... See more keywords
Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2016.1259167
Abstract: Abstract Objective: To assess the economic impact of urinary tract infections (UTIs) and genital mycotic infections (GMIs) among patients with type 2 diabetes mellitus (T2DM) initiated on canagliflozin. Methods: Administrative claims data from April 2013… read more here.
Keywords: urinary tract; initiated canagliflozin; among patients; tract infections ... See more keywords